News & Events

BRIEF-S107 million series C raise for HighTide Therapeutics

January 06, 2023

source from:The pharma letter


Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.


The company, which has a footprint in both China and the USA, is working on multifunctionaltherapies, including lead candidate HTD801, a first-in-class candidate for conditionsincluding type 2 diabetes and non-alcoholic steatohepatitis (NASH).


HighTide will use the money to advance clinical development as well as commercializationand business development.


With a Phase II trial in type 2 diabetes near completion, the company has also initiated mid-stage research in NASH and has secured US Fast Track designation for the candidate in NASHas well as primary sclerosing cholangitis (PSC).
Share on WeChat circle of friends ×
Open WeChat
Use Scan to share web pages with your friends.

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

We will contact you as soon as possible

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

© 2024 HighTide Therapeutics, Inc.

Legal StatementPrivacy PolicyCookie Policy

收起
En

Follow Us

© 2024 HighTide Therapeutics, Inc.